NCT00922948

Brief Summary

The purpose of this study is to verify the oncological efficacy and safety of cryoablation and radiofrequency ablation for the treatment of small renal tumors.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2010

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 16, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 17, 2009

Completed
9 months until next milestone

Study Start

First participant enrolled

March 1, 2010

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2015

Completed
Last Updated

July 27, 2016

Status Verified

July 1, 2016

Enrollment Period

5 years

First QC Date

June 16, 2009

Last Update Submit

July 26, 2016

Conditions

Keywords

Radiofrequency ablationCryosurgeryRenal cancers

Outcome Measures

Primary Outcomes (1)

  • Treatment failure rate.

    Baseline, Weeks 6, 12, 24, 36, 48

Secondary Outcomes (4)

  • Renal function - GFR of less than 60 ml per min per 1.73 m2. Serum creatinine and creatinine clearance.

    Baseline, Weeks 6, 12, 24, 36 and 48

  • Average percentage decrease in tumor size.

    Baseline, Weeks 6, 12, 24, 36 and 48

  • Intra and post-operative complications rates.

    Weeks 6, 12, 24, 36 and 48

  • Quality of life data.

    Baseline, Weeks 6, 12, 24, 36 and 48

Study Arms (2)

Cryoablation

EXPERIMENTAL
Procedure: Cryoablation

Radiofrequency ablation

ACTIVE COMPARATOR

Radiofrequency ablation

Procedure: Radiofrequency ablation

Interventions

CryoablationPROCEDURE

Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.

Cryoablation

Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.

Radiofrequency ablation

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with tumors that progress in size while on a watchful waiting protocol;
  • Patients with multiple tumors;
  • Patients with a tumor in a solitary kidney;
  • Patients with poor renal function and a renal tumor;
  • Patients with significant co-morbidities that may benefit from a less invasive approach.

You may not qualify if:

  • Large tumors \> 4.0cm;
  • Unable to have a general anesthetic;
  • Unable to comply with follow-up protocol (i.e., routine CT or MRI and a follow-up biopsy);
  • Uncorrectable bleeding diathesis;
  • Evidence of metastatic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

McMaster Institute of Urology - St. Joseph's Healthcare Hamilton

Hamilton, Ontario, L8N 4A6, Canada

Location

MeSH Terms

Conditions

Kidney Neoplasms

Interventions

CryosurgeryRadiofrequency Ablation

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Ablation TechniquesSurgical Procedures, OperativeRadiofrequency TherapyTherapeutics

Study Officials

  • Anil Kapoor, MD

    McMaster Institute of Urology, McMaster University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, FRCSC

Study Record Dates

First Submitted

June 16, 2009

First Posted

June 17, 2009

Study Start

March 1, 2010

Primary Completion

March 1, 2015

Study Completion

March 1, 2015

Last Updated

July 27, 2016

Record last verified: 2016-07

Locations